Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates

Mostrar otras versiones (1)

Many different vaccine candidates against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to pro...

Descripción completa

Detalles Bibliográficos
Autores principales: van Doremalen, Neeltje, Fischer, Robert J., Schulz, Jonathan E., Holbrook, Myndi G., Smith, Brian J., Lovaglio, Jamie, Petsch, Benjamin, Munster, Vincent J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282095/
https://www.ncbi.nlm.nih.gov/pubmed/34268507
http://dx.doi.org/10.1101/2021.07.07.451505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282095/
https://www.ncbi.nlm.nih.gov/pubmed/34268507
http://dx.doi.org/10.1101/2021.07.07.451505

Ejemplares similares